Literature DB >> 19327115

The host response and molecular pathogenesis associated with respiratory syncytial virus infection.

Christine M Oshansky1, Wenliang Zhang, Elizabeth Moore, Ralph A Tripp.   

Abstract

Since the isolation of respiratory syncytial virus (RSV) in 1956, its significance as an important human pathogen in infants, the elderly and the immunocompromised has been established. Many important mechanisms contributing to RSV infection, replication and disease pathogenesis have been uncovered; however, there is still insufficient knowledge in these and related areas, which must be addressed to facilitate the development of safe and effective vaccines and therapeutic treatments. A better understanding of the molecular pathogenesis of RSV infection, particularly the host-cell response and transcription profiles to RSV infection, is required to advance disease intervention strategies. Substantial information is accumulating regarding how RSV proteins modulate molecular signaling and regulation of cytokine and chemokine responses to infection, molecular signals regulating programmed cell death, and innate and adaptive immune responses to infection. This review discusses RSV manipulation of the host response to infection and related disease pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19327115      PMCID: PMC2711508          DOI: 10.2217/fmb.09.1

Source DB:  PubMed          Journal:  Future Microbiol        ISSN: 1746-0913            Impact factor:   3.165


  235 in total

Review 1.  Toll-like receptors: linking innate and adaptive immunity.

Authors:  Chandrashekhar Pasare; Ruslan Medzhitov
Journal:  Adv Exp Med Biol       Date:  2005       Impact factor: 2.622

2.  Antigenic structure of human respiratory syncytial virus fusion glycoprotein.

Authors:  J A López; R Bustos; C Orvell; M Berois; J Arbiza; B García-Barreno; J A Melero
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

3.  The structure of the respiratory syncytial virus.

Authors:  J Joncas; L Berthiaume; V Pavilanis
Journal:  Virology       Date:  1969-07       Impact factor: 3.616

4.  Growth of respiratory syncytial virus in primary epithelial cells from the human respiratory tract.

Authors:  Peter F Wright; Mine R Ikizler; Ricardo A Gonzales; Kecia N Carroll; Joyce E Johnson; Jay A Werkhaven
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

Review 5.  Community respiratory virus infections following lung transplantation.

Authors:  J L Billings; M I Hertz; C H Wendt
Journal:  Transpl Infect Dis       Date:  2001-09       Impact factor: 2.228

6.  Identification of a linear heparin binding domain for human respiratory syncytial virus attachment glycoprotein G.

Authors:  S A Feldman; R M Hendry; J A Beeler
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

7.  Respiratory syncytial virus G protein and G protein CX3C motif adversely affect CX3CR1+ T cell responses.

Authors:  Jennifer Harcourt; Rene Alvarez; Les P Jones; Christine Henderson; Larry J Anderson; Ralph A Tripp
Journal:  J Immunol       Date:  2006-02-01       Impact factor: 5.422

8.  Human cytotoxic T cells stimulated by antigen on dendritic cells recognize the N, SH, F, M, 22K, and 1b proteins of respiratory syncytial virus.

Authors:  A H Cherrie; K Anderson; G W Wertz; P J Openshaw
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

9.  Macrophage impairment underlies airway occlusion in primary respiratory syncytial virus bronchiolitis.

Authors:  Jennifer L Reed; Yambasu A Brewah; Tracy Delaney; Timothy Welliver; Timothy Burwell; Ebony Benjamin; Ellen Kuta; Alexander Kozhich; LuAnn McKinney; JoAnn Suzich; Peter A Kiener; Luis Avendano; Luis Velozo; Alison Humbles; Robert C Welliver; Anthony J Coyle
Journal:  J Infect Dis       Date:  2008-12-15       Impact factor: 5.226

10.  Role of alpha/beta interferons in the attenuation and immunogenicity of recombinant bovine respiratory syncytial viruses lacking NS proteins.

Authors:  Jean-Francois Valarcher; Julie Furze; Sara Wyld; Roy Cook; Karl-Klaus Conzelmann; Geraldine Taylor
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

View more
  35 in total

1.  Prophylactic treatment with a G glycoprotein monoclonal antibody reduces pulmonary inflammation in respiratory syncytial virus (RSV)-challenged naive and formalin-inactivated RSV-immunized BALB/c mice.

Authors:  Gertrud U Radu; Hayat Caidi; Congrong Miao; Ralph A Tripp; Larry J Anderson; Lia M Haynes
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

2.  Antibody response to the central unglycosylated region of the respiratory syncytial virus attachment protein in mice.

Authors:  Yoshihiko Murata; Seana C Catherman
Journal:  Vaccine       Date:  2012-06-19       Impact factor: 3.641

Review 3.  Therapeutic targeting of respiratory syncytial virus G-protein.

Authors:  Lawrence M Kauvar; Jennifer L Harcourt; Lia M Haynes; Ralph A Tripp
Journal:  Immunotherapy       Date:  2010-09       Impact factor: 4.196

Review 4.  The airway epithelium: soldier in the fight against respiratory viruses.

Authors:  Marjolaine Vareille; Elisabeth Kieninger; Michael R Edwards; Nicolas Regamey
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

5.  Respiratory syncytial virus F and G proteins induce interleukin 1alpha, CC, and CXC chemokine responses by normal human bronchoepithelial cells.

Authors:  Christine M Oshansky; James P Barber; Jackelyn Crabtree; Ralph A Tripp
Journal:  J Infect Dis       Date:  2010-04-15       Impact factor: 5.226

6.  Effects of anti-g and anti-f antibodies on airway function after respiratory syncytial virus infection.

Authors:  Junyan Han; Katsuyuki Takeda; Meiqin Wang; Wanjiang Zeng; Yi Jia; Yoshiki Shiraishi; Masakazu Okamoto; Azzeddine Dakhama; Erwin W Gelfand
Journal:  Am J Respir Cell Mol Biol       Date:  2014-07       Impact factor: 6.914

7.  Prophylaxis with a respiratory syncytial virus (RSV) anti-G protein monoclonal antibody shifts the adaptive immune response to RSV rA2-line19F infection from Th2 to Th1 in BALB/c mice.

Authors:  Seyhan Boyoglu-Barnum; Tatiana Chirkova; Sean O Todd; Thomas R Barnum; Kelsey A Gaston; Patricia Jorquera; Lia M Haynes; Ralph A Tripp; Martin L Moore; Larry J Anderson
Journal:  J Virol       Date:  2014-07-02       Impact factor: 5.103

8.  Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice.

Authors:  Wenliang Zhang; Youngjoo Choi; Lia M Haynes; Jennifer L Harcourt; Larry J Anderson; Les P Jones; Ralph A Tripp
Journal:  J Virol       Date:  2009-10-28       Impact factor: 5.103

9.  Within-host whole-genome deep sequencing and diversity analysis of human respiratory syncytial virus infection reveals dynamics of genomic diversity in the absence and presence of immune pressure.

Authors:  Yonatan H Grad; Ruchi Newman; Michael Zody; Xiao Yang; Ryan Murphy; James Qu; Christine M Malboeuf; Joshua Z Levin; Marc Lipsitch; John DeVincenzo
Journal:  J Virol       Date:  2014-04-16       Impact factor: 5.103

Review 10.  The infectious march: the complex interaction between microbes and the immune system in asthma.

Authors:  Terianne Wong; Gary Hellermann; Shyam Mohapatra
Journal:  Immunol Allergy Clin North Am       Date:  2010-11       Impact factor: 3.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.